RBC Bioscience Corporation (6848.TWO)
TWD 18.7
(2.75%)
TWD 18.7
(2.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 13.2 Million | 6.6 Million | -25.29 Million | 205.67 Million | 40.15 Million |
| Net Income | 7.87 Million | 4.91 Million | 35.94 Million | 177.34 Million | 14.45 Million |
| Depreciation & Amortization | 19.19 Million | 19.73 Million | 19.85 Million | 13.83 Million | 9.92 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -5.39 Million | -18.1 Million | -46.24 Million | 6.04 Million | 3.76 Million |
| Other non-cash items | 9.67 Million | 7.41 Million | 6.15 Million | 3.62 Million | 12.01 Million |
| Investing Cash Flow | 1 Million | 12.6 Million | -425.66 Million | -119.5 Million | -9.93 Million |
| Investments in PPE | -6.46 Million | -10.04 Million | -450.11 Million | -118.41 Million | -9.08 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | 27.68 Million | 25.16 Million | - | - |
| Other Investing Activities | 7.46 Million | -5.03 Million | -723 Thousand | -1.28 Million | -855 Thousand |
| Financing Cash Flow | -24.96 Million | -40.75 Million | 424.48 Million | -5.49 Million | -8.89 Million |
| Debt repayment | -8.96 Million | -27.26 Million | -395.68 Million | -55 Million | -4.52 Million |
| Dividends payments | -14.53 Million | -11.79 Million | -14.38 Million | -54.76 Million | -12.27 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | 50 Million | - | - |
| Other Financing Activities | -5 Million | 286 Thousand | 43.65 Million | 55 Million | 7.9 Million |
| Accounts receivables | 2.48 Million | -811 Thousand | 27.53 Million | -26.66 Million | -4.4 Million |
| Accounts payables | -6.99 Million | - | - | - | - |
| Inventory | 2.77 Million | 3.99 Million | 9.58 Million | -35.64 Million | 3.16 Million |
| Other working capital | -3.72 Million | -7.14 Million | -19.11 Million | -4.67 Million | 5 Million |
| Cash at beginning of period | 75.92 Million | 97.46 Million | 123.94 Million | 43.26 Million | 21.94 Million |
| Cash at end of period | 65.17 Million | 75.92 Million | 97.46 Million | 123.94 Million | 43.26 Million |
| Capital Expenditure | -6.46 Million | -10.04 Million | -450.11 Million | -118.41 Million | -9.08 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -10.75 Million | -21.53 Million | -26.47 Million | 80.68 Million | 21.31 Million |
| Free Cash Flow | 6.74 Million | -3.44 Million | -475.41 Million | 87.26 Million | 31.07 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 6.57 Million | 6.57 Million | 7.87 Million | 2.06 Million | 2.06 Million | 1.15 Million |
| Depreciation & Amortization | 4.65 Million | 4.65 Million | 19.19 Million | 4.57 Million | 4.57 Million | 4.79 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -4.23 Million | -4.23 Million | -5.39 Million | 2.72 Million | 2.72 Million | -1.95 Million |
| Other non-cash items | 5.75 Million | 5.75 Million | 9.67 Million | 324 Thousand | 324 Thousand | -7.07 Million |
| Investing Cash Flow | -1.64 Million | -1.64 Million | 1 Million | -2.05 Million | -2.05 Million | 2.55 Million |
| Investments in PPE | -1.64 Million | -1.64 Million | -6.46 Million | -1.82 Million | -1.82 Million | -675 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | 7.46 Million | -235 Thousand | -235 Thousand | 3.23 Million |
| Financing Cash Flow | -5.33 Million | -5.33 Million | -24.96 Million | -8.11 Million | -8.11 Million | -4.36 Million |
| Debt repayment | -9.94 Million | - | -8.96 Million | - | - | - |
| Dividends payments | - | - | -14.53 Million | -7.26 Million | -7.26 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -5.33 Million | -5.33 Million | -5 Million | -845.5 Thousand | -845.5 Thousand | -4.36 Million |
| Accounts receivables | -7.21 Million | -7.21 Million | 2.48 Million | 120.5 Thousand | 120.5 Thousand | 1.11 Million |
| Accounts payables | 7.59 Million | - | - | - | - | - |
| Inventory | 1.32 Million | 1.32 Million | 2.77 Million | 296 Thousand | 296 Thousand | 1.09 Million |
| Other working capital | 1.65 Million | 1.65 Million | -3.72 Million | 2.3 Million | 2.3 Million | -4.17 Million |
| Cash at beginning of period | 65.17 Million | - | 75.92 Million | - | - | - |
| Cash at end of period | 5.77 Million | 5.77 Million | 65.17 Million | -482 Thousand | -482 Thousand | -4.89 Million |
| Capital Expenditure | -1.64 Million | -1.64 Million | -6.46 Million | -1.82 Million | -1.82 Million | -675 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -59.4 Million | 5.77 Million | -10.75 Million | -482 Thousand | -482 Thousand | -4.89 Million |
| Free Cash Flow | 11.11 Million | 11.11 Million | 6.74 Million | 7.86 Million | 7.86 Million | -3.75 Million |
4379
2754
0410
9248
0670
ERDLF